Income Statements for Bellicum Pharmaceuticals, Inc. (BLCM)

Add BLCM to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Bellicum Pharmaceuticals, Inc.

Symbol

BLCM

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, Houston

Sector

Healthcare

Industry

Biotechnology

Website

https://www.bellicum.com

ISIN

US0794814048

CIK

1358403

CUSIP

079481404

UEI

-

LEI

-

Business Description

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders.